P
Prelude Therapeutics
The discovery and development of novel, small molecule therapies to treat cancer
About Prelude Therapeutics
Prelude Therapeutics, a clinical-stage precision oncology company, was established in Wilmington, Delaware, in 2016 by founder and CEO Dr. Kris Vaddi. Dr. Vaddi, a founding scientist at Incyte Corp, leveraged his extensive experience, including his role in developing approved drugs like Jakafi®, to create a company focused on developing targeted cancer therapies. The company began with $5 million in seed funding at the University of Delaware STAR Campus before moving to the Delaware Innovation Space.
The company operates within the competitive oncology market, focusing on the discovery and development of small molecule drugs that target key driver mechanisms in cancers with high unmet medical needs. As a clinical-stage biopharmaceutical firm, Prelude does not yet have approved products for sale and its revenue is primarily derived from collaboration agreements. The company's financial strategy has included several funding rounds, starting with a Series A of $20 million in 2016 and culminating in a successful Initial Public Offering (IPO) in September 2020, which raised approximately $181.9 million after underwriters fully exercised their option to purchase additional shares. A subsequent public offering in May 2023 was expected to generate gross proceeds of around $100 million.
Prelude's core business involves identifying and validating promising drug targets within cancer cell signaling pathways to develop differentiated, and potentially best-in-class, therapies. Its diverse pipeline includes several novel drug candidates. A key area of focus is on protein degradation, featuring first-in-class SMARCA2 protein degraders and KAT6A selective degraders. The oral SMARCA2 degrader, PRT7732, is currently in clinical trials with preliminary data expected by the end of 2025. To concentrate resources on this promising oral candidate, development of the intravenous SMARCA2 degrader, PRT3789, has been paused. The company is also advancing its oral KAT6A degrader program, with plans to file an Investigational New Drug (IND) application in the first half of 2026. Furthermore, Prelude is developing next-generation degrader antibody conjugates (ADCs) through strategic partnerships with companies like AbCellera and Merck, aiming to deliver targeted drug payloads to cancer cells.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Wilmington, United States
- Employees
- 107
- Open positions
- 1
- Dealroom signal
- 28.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Apr 2026 | $90M | — | RA Capital Management | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Nov 2025 | $25M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Prelude Therapeutics is 6.8K monthly website visits, down 4.2% over the last three months. Prelude Therapeutics's team declined 13% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Prelude Therapeutics in the Wilmington ecosystem
The Prelude Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Prelude Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prelude Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.













